Lupin Secures Tentative US FDA Approval For Pitolisant Tablets

The approval marks a significant milestone for Lupin, strengthening its central nervous system (CNS) portfolio and enhancing its presence in the U.S. generics market. The tablets will be manufactured at Lupin’s Nagpur facility in India, reinforcing the company’s global supply chain capabilities.

Drug And Approval Details
Pitolisant belongs to the class of H3 receptor antagonists, which regulate neurotransmitters involved in sleep and wakefulness. Lupin’s version has been deemed bioequivalent to Wakix, the reference drug approved in the U.S. The tentative approval allows Lupin to prepare for eventual market launch once patent and exclusivity barriers are cleared.

Strategic Impact And Industry Outlook
Analysts note that narcolepsy treatment is a growing therapeutic area, with rising demand for effective solutions. Lupin’s entry into this segment positions it to capture market share in the U.S. while diversifying its CNS offerings. The approval also highlights Lupin’s continued focus on complex generics and specialty therapies.

Key Highlights

• Lupin receives tentative US FDA approval for Pitolisant tablets
• Strengths approved: 4.45 mg and 17.8 mg
• Indicated for excessive daytime sleepiness and cataplexy in narcolepsy patients
• Manufactured at Lupin’s Nagpur facility in India
• Bioequivalent to Wakix, strengthening CNS portfolio in the U.S.

Sources: Business Standard, Pharmabiz, Rediff Money, Lupin press release